Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity

  • Geller, Ron
  • Revuelta, Julia
  • Rusu, Luciana
  • Francés-Gómez, Clara
  • Trapero, Elena
  • Iglesias, Susana
  • Calvo Pinilla, Eva
  • Blázquez, Ana-Belén
  • Gutiérrez-Adán, Alfonso
  • Konuparamban, Acsah
  • Moreno, Oscar
  • Gómez-Martínez, María
  • Forcada-Nadal, Alicia
  • López-Redondo, Marisa
  • Llácer, José Luis
  • Llop, Jordi
  • Martín-Acebes, M. A.
  • Fernández-Mayoralas, Alfonso
Enveloped viruses enter cells by binding to receptors present on host cell membranes, which trigger internalization and membrane fusion. For many viruses, this either directly or indirectly involves interaction with membrane-anchored carbohydrates, such as heparan sulfate, providing a potential target for a broad-spectrum antiviral approach. Based on this hypothesis, we screened a library of functionalized chitosan sulfates that mimic heparan sulfate in cellular membranes for inhibition of SARS-CoV-2 and respiratory syncytial virus (RSV) entry. An array of compounds blocking SARS-CoV-2 and RSV were identified, with the lead compound displaying broad-spectrum activity against multiple viral strains and clinical isolates. Mechanism of action studies showed the drug to block viral entry irreversibly, likely via a virucidal mechanism. Importantly, the drug was non-toxic in vivo and showed potent post-exposure therapeutic activity against both SARS-CoV-2 and RSV. Together, these results highlight the potential of functionalized carbohydrates as broad-spectrum antivirals targeting respiratory viruses., Funding for this project was provided by grants SGL2021-03-009, SGL2103053, and SGL2021-03-052 from European Union NextGenerationEU/PRTR through the CSIC Global Health Platform established by EU Council Regulation 2020/2094, to RG, to MAM-A, J. R., A. F.-M., J.L.L, and the IBV-Covid19-Pipeline acknowledge the financial support provided by CSIC (grants CSIC-COV19-013, CSIC-COV19-082) and the MICIN (grants PID2019-105337RB-C21, PID2020-120322RB-C21, PID2020-116880GB-I00). RG also acknowledges funding from the Generalitat Valenciana (GVA, GVCOVID19-2020-05). MAM-A acknowledges funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101137506 (NAVIPP)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity

  • Revuelta, Julia
  • Rusu, Luciana
  • Francés-Gómez, Clara
  • Trapero, Elena
  • Iglesias, Susana
  • Pinilla, Eva Calvo
  • Blázquez, Ana-Belén
  • Gutiérrez-Adán, Alfonso
  • Konuparamban, Acsah
  • Moreno, Oscar
  • Gómez Martínez, María
  • Forcada-Nadal, Alicia
  • López-Redondo, Marisa
  • Avilés-Alía, Ana Isabel
  • Llácer, José Luis
  • Llop, Jordi
  • Martín-Acebes, M. A.
  • Geller, Ron
  • Fernández-Mayoralas, Alfonso
Enveloped viruses enter cells by binding to receptors present on host cell membranes, which trigger internalization and membrane fusion. For many viruses, this either directly or indirectly involves interaction with membrane-anchored carbohydrates, such as heparan sulfate, providing a potential target for a broad-spectrum antiviral approach. Based on this hypothesis, we screened a library of functionalized chitosan sulfates that mimic heparan sulfate in cellular membranes for inhibition of SARS-CoV-2 and respiratory syncytial virus (RSV) entry. An array of compounds blocking SARS-CoV-2 and RSV were identified, with the lead compound displaying broad-spectrum activity against multiple viral strains and clinical isolates. Mechanism of action studies showed the drug to block viral entry irreversibly, likely via a virucidal mechanism. Importantly, the drug was non-toxic in vivo and showed potent post-exposure therapeutic activity against both SARS-CoV-2 and RSV. Together, these results highlight the potential of functionalized carbohydrates as broad-spectrum antivirals targeting respiratory viruses., This work acknowledges the use of ICTS-ReDIB, supported by the Ministry of Science, Innovation and Universities (MICIU) at biomaGUNE. We thank Raquel Palao (ICTP-CSIC) for the GPC analysis. Funding for this project was provided by grants SGL2021-03-009, SGL2103053, and SGL2021-03-052 from European Union NextGenerationEU/PRTR through the CSIC Global Health Platform established by EU Council Regulation 2020/2094, to RG, to MAM-A, J. R., A. F.-M., J.L.L, and the IBV-Covid19-Pipeline acknowledge the financial support provided by CSIC (grants CSIC-COV19-013, CSIC-COV19-082) and the MICIN (grants PID2019-105337RB-C21, PID2020-120322RB-C21, PID2020-116880GB-I00). RG also acknowledges funding from the Generalitat Valenciana (GVA, GVCOVID19-2020-05). MAM-A acknowledges funding from the European Union’s Horizon Europe research and innovation program under grant agreement number 101137506 (NAVIPP)., Peer reviewed